Pharmaceuticals

Global Biologics Market Report 2026: Emerging Trends and Growth Scenarios

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the biologics market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Biologics Market in 2026, and what figure is it projected to hit by 2030?

The biologics market has experienced significant expansion in recent years. This market is anticipated to expand from $495.56 billion in 2025 to $540.46 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.1%. The historical development in this sector can be attributed to several factors, including the scarcity of biologics, a historical reliance on conventional treatments, the rising occurrence of immune-related conditions, improvements in healthcare infrastructure, and heightened physician awareness leading to more prescriptions.

The biologics market is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $827.24 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.2%. Factors contributing to this growth during the forecast period include the creation of new monoclonal antibodies, the broader application of mRNA and viral vector vaccines, the rising embrace of personalized biologic treatments, increased government backing and financial support for biologics, and the incorporation of digital health and patient monitoring systems. Key trends expected throughout the same period encompass a greater acceptance of monoclonal antibodies and therapeutic proteins, an increase in vaccine development efforts, particularly mRNA and viral vector types, the wider distribution of prescription biologics through hospital pharmacies, an intensified focus on personalized medicine and specific biologic therapies, and the merging of biologics with cutting-edge healthcare technologies and patient tracking.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3606&type=smp

Which Drivers Are Affecting Market Participation In The Biologics Market?

The rising need for personalized medicine is significantly boosting the global biologics market. Personalized medicine, also known as precision medicine, represents a medical strategy that adapts healthcare and treatments to the distinct characteristics of individual patients. This approach allows for the customization of biological therapies based on a patient’s specific genetic and clinical profile, thereby transforming the healthcare landscape. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Consequently, the growing demand for personalized medicine is propelling the biologics market forward.

What Segment Categories Are Covered In The Biologics Market?

The biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines

2) By Drug Classification: Branded Drugs, Generic Drugs

3) By Route Of Administration: Oral, Other Route Of Administration

4) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies (MAbs): Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Therapeutic Proteins: Hormones, Enzymes, Cytokines, Fusion Proteins

3) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines, Viral Vector Vaccines

How Are New Market Trends Shaping The Landscape Of The Biologics Market?

Leading companies in the biologics market are concentrating on developing innovative products, such as biosimilars, to provide cost-effective alternatives to original biologic therapies. Biosimilars are biologic products highly similar to an already approved reference biologic, demonstrating no significant differences in safety, efficacy, or quality, which helps reduce treatment costs and increase patient access to advanced therapies. For instance, in July 2025, Biocon Biologics, a subsidiary of Biocon Limited, an India-based biopharmaceutical company, introduced Nepexto in Australia, which is a biosimilar to Enbrel (etanercept). Nepexto is a fusion-protein biologic designed to inhibit tumor necrosis factor-alpha (TNF-a), a key inflammatory mediator in autoimmune conditions. It is composed of recombinant DNA-derived protein that mimics the binding activity of the original etanercept molecule, delivering comparable efficacy and safety while making treatment more accessible. Its unique features include high biosimilarity backed by robust clinical data, regulatory approvals, and an established supply chain via its local partner Generic Health, making it a strong option for long-term management of diseases such as rheumatoid arthritis, psoriasis, and ankylosing spondylitis.

Which Major Firms Are Strengthening Their Position In The Biologics Market?

Major companies operating in the biologics market are Merck & Co. Inc., AbbVie Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Amgen Inc., Shanghai Fosun Pharmaceuticals, Bayer AG, Novartis AG, BiosanaPharma, WuXi, Teva UK Limited, AstraZeneca, Abbott Laboratories, Vectura Group, Fujifilm, Lonza, Seqens, Piramal Pharma Solutions, Corden Pharma, Procos SpA and BSP Pharmaceuticals., Microgen, Geropharm, Valenta, NovaMedica, SynBi, Rani Therapeutics, Enteris BioPharma, Allena Pharmaceuticals, Biogen Inc., Emisphere Technologies Inc., Apotex, Gilead Sciences

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biologics-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Biologics Market?

North America was the largest region in the biologics market in 2025. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biologics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3606&type=smp

Browse Through More Reports Similar to the Global Biologics Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Orthobiologics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthobiologics-devices-and-equipment-global-market-report

Oral Biologics And Biosimilar Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795